Table 3.
Treatment-related toxicities
| Adverse event | Grade of toxicity | |||
|---|---|---|---|---|
| Grade 1 (%) | Grade 2 (%) | Grade 3 (%) | Grade 4 (%) | |
| Hematologic | ||||
| Anemia | 26 (30 %) | 20 (23 %) | 10 (11 %) | 1 (1 %) |
| Leucopenia | 2 (2 %) | 24 (27 %) | 50 (57 %) | 5 (6 %) |
| Thrombocytopenia | 0 | 25 (28 %) | 55 (63 %) | 6 (7 %) |
| Nonhematologic | ||||
| Nausea | 23 (26 %) | 4 (5 %) | 0 | 0 |
| APTT/PT prolongation | 21 (24 %) | 5 (6 %) | 2 (2 %) | |
| Hypofibrinogenemia | 18 (20 %) | 5 (6 %) | 2 (2 %) | 1 (1 %) |
| ALT elevation | 15 (17 %) | 3 (3 %) | 0 | 0 |
| Hyperbilirubinaemia | 6 (7 %) | 2 (2 %) | 0 | 0 |
| Hyperglycemia | 6 (7 %) | 3 (3 %) | 0 | 0 |
| Raised creatinine | 9 (10 %) | 0 | 0 | 0 |
| Paresthesias | 11 (13 %) | 0 | 0 | 0 |
| Palpitations | 7 (8 %) | 0 | 0 | 0 |
Table shows number of cycles affected and percentage of total cycles in which the respective toxicity occurred
APTT activated partial thromboplastin time, PT prothrombin time, ALT alanine aminotransferase